Evidence map›Paper›PMID 40527893›Full record

ArticleNature communications2025

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.

Atsuo Kanno, Takuya Kito, Masashi Maeda, Shanni Yamaki, Yasushi Amano, Takuya Shimomura, Margarita Anisimova, Naomi Kanazawa, Koichiro Suzuki, Amir Razai and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Atsuo Kanno *Arialys Therapeutics, Inc., La Jolla, CA, USA.
Takuya Kito *Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0009-0009-9355-3870
Masashi MaedaArialys Therapeutics, Inc., La Jolla, CA, USA.
Shanni YamakiArialys Therapeutics, Inc., La Jolla, CA, USA.
Yasushi AmanoAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-7190-7537
Takuya ShimomuraAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-6769-4655
Margarita AnisimovaCenter for Neuroscience, University of California, Davis, CA, USA.
Naomi KanazawaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-8027-4447
Koichiro SuzukiAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Amir RazaiArialys Therapeutics, Inc., La Jolla, CA, USA.
Takuma MiharaAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Kaori KuboAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Takeshi ShimadaAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Koji NakamuraAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Naoko NomuraAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Yuji KondoAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Akira OkimotoAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0003-3115-2800
Azusa SugiyamaAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Deborah ParkCenter for Neuroscience, University of California, Davis, CA, USA.
Ivar SteinCenter for Neuroscience, University of California, Davis, CA, USA.
Samuel PetshowCenter for Neuroscience, University of California, Davis, CA, USA.
Valentin VandendorenVanadro, LLC, Waukee, IA, USA.ORCID http://orcid.org/0009-0005-9099-4495
Sanela BilicVanadro, LLC, Waukee, IA, USA.
Roghiye KazimiArialys Therapeutics, Inc., La Jolla, CA, USA.
Vallari EastmanArialys Therapeutics, Inc., La Jolla, CA, USA.
Scott J SnipasArialys Therapeutics, Inc., La Jolla, CA, USA.
Mathew MitchellArialys Therapeutics, Inc., La Jolla, CA, USA.ORCID http://orcid.org/0009-0007-5717-8634
Mari MaurerArialys Therapeutics, Inc., La Jolla, CA, USA.
Marty JefsonArialys Therapeutics, Inc., La Jolla, CA, USA.
Jay LichterArialys Therapeutics, Inc., La Jolla, CA, USA.
Daisuke YamajukuAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.
Hiroki ShiraiAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0009-0004-1019-6120
Megumi AdachiAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0003-3404-6640
Daniel J HoeppnerAstellas Pharma Inc., Tsukuba, Ibaraki, Japan.ORCID http://orcid.org/0000-0002-0886-5215
Satoshi KuboArialys Therapeutics, Inc., La Jolla, CA, USA.
Karen ZitoCenter for Neuroscience, University of California, Davis, CA, USA.
Takahiro IizukaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-7234-0720
Peter FlynnArialys Therapeutics, Inc., La Jolla, CA, USA.
Mitsuyuki MatsumotoArialys Therapeutics, Inc., La Jolla, CA, USA. mmatsumoto@arialysrx.com.ORCID http://orcid.org/0000-0002-1172-2354

Funding

Astellas Pharma (Astellas) N/A
6 · The paper itself

Abstract

Anti-NMDA receptor (NMDAR) encephalitis is a devastating disease with severe psychiatric and neurological symptoms believed to be caused by pathogenic autoantibodies that bind to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) crosslinking adjacent NMDARs and driving their internalization. Here we describe ART5803, a humanized monovalent antibody, as a potential therapy for anti-NMDAR encephalitis. ART5803 binds with a high affinity (K

Indexed as

Antibodies, Monoclonal, HumanizedAnti-N-Methyl-D-Aspartate Receptor EncephalitisReceptors, N-Methyl-D-AspartateAnimalsAutoantibodiesCallithrixDisease Models, AnimalFemaleHumansMacaca fascicularisMaleAntibodies, Monoclonal, HumanizedAutoantibodiesReceptors, N-Methyl-D-Aspartate

Identifiers

PMID40527893
PMCPMC12174348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.